Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Benitec Biopharma Inc. (BNTC)

Benitec Biopharma reports positive interim BB-301 Phase 1b/2a results for high dose

Positive Impact 3 of 5 product/contract Written later

Benitec Biopharma announced positive interim Phase 1b/2a clinical results for high dose BB-301 and continued durable improvements for low dose BB-301 in patients with oculopharyngeal muscular dystrophy (OPMD). The company reports a 100% responder rate across all patients treated to date and no serious adverse events, but the filing contains clinical data only, with no financial results, and the company cautions that interim results may not be maintained.

Key points

  • All six Cohort 1 (low dose) patients and all three Cohort 2 (high dose) patients are formal responders to BB-301.
  • At 3 months, 100% of Cohort 2 patients met the statistical criteria for improved throat emptying ability, versus 67% of Cohort 1 patients.
  • No serious adverse events have been reported in any patient treated with BB-301 to date.
  • The company plans a pivotal study of BB-301 in mid-2027.

The filing

CompanyBenitec Biopharma Inc. (BNTC)
Form8-K, current report
Filed with the SECOct 28, 2026, 8:03 AM ET
Accession number0001193125-26-435159

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.